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SAMMANFATTNING 
Cellcykeln benämns den tid som en cell tillbringar mellan två celldelningar. Cellcykeln 
innefattar flera parallella processer som alla måste slutföras innan en cell är mogen för 
delning. För det första måste alla cellens strukturella komponenter (RNA, proteiner och 
membranlipider) fördubblas och detta sker kontinuerligt genom cellcykeln.  
Dessutom måste arvsmassan och några av de kromosomala proteinerna fördubblas och detta 
sker under ett avgränsat intervall ungefär mitt i cellcykeln (S-fasen).  
 
På ömse sidor om S-fasen finns två ”gaps” som brukar kallas G1 och G2. När celler har 
passerat en punkt i G1-fasen är de oåterkalleligen programmerade för att progrediera genom 
återstoden av cellcykeln och kommer genomgå nästa celldelning. Ungefär fyra timmar efter 
mitos befinner sig normalcellen i ett stadium av obeslutsamhet. Under denna fas (G1pm) 
påverkas cellen av yttre faktorer som exempelvis tillgång till tillväxtfaktorer och närhet till 
andra celler att fatta ett beslut om den skall fortsätta mot S-fas eller utträda ur cellcykeln och 
inträda i ett reversibelt vilostadium – G0. G1pm-fasen är alltid av konstant längd (fyra timmar) 
och åtföljs av en variabel del, G1ps, under vilken cellen bygger upp sina strukturkomponenter 
med varierande hastighet. En liten cell tillbringar en relativt längre tid i G1ps än en större. 
Tanken är att alla storleksskillnader mellan celler skall vara utjämnade när S-fasen initieras. 
Till skillnad från normala celler saknar transformerade celler förmågan att utträda i G0 under 
suboptimala förhållanden. 
Denna artikel syftar till att sammanfatta hur normala och transformerade celler förhåller sig 
till G0-blockeringen samt hur enskilda faktorer styr de båda cellslagens förhållande till 
proliferationshämning och "sustained proliferation". 
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SUMMARY 
The cell cycle is the time a cell spends between two cell divisions. The cell cycle includes 
several parallel processes, all of which must be completed before a cell is mature for dividing.  
In the first place, all subcomponents (RNA, protein and membrane lipids) need to double in 
quantity and this occurs continuously through the cell cycle. Furthermore, the genome and 
some chromosomal proteins must double and this take place during a limited interval in the 
middle of the cell cycle (S-phase). On either side of the S-phase are two "gaps" which is 
called G1 and G2. 
When the cell has passed a point in the G-phase they are irreversibly programmed to progress 
through the remaining of the cell cycle and will undergo the next cell division. When a cell 
have passed a point in the G1 phase, approximately four hours after mitosis, a normal cell is in 
a state of indecision. During this phase (G1pm), the cell is affected by external factors, such as 
presence of certain growth factors and proximity to other cells  to make a decision whether to 
continue toward S-phase or exit the cell cycle and enter a reversible resting stage-G0.  
G1pm phase is always of constant length (four hours), followed by a variable phase of G1 
(G1ps) during which the cell builds its structural components with varying speed. 
A small cell spend a relatively longer time in G1ps than a larger one. The idea is that any size 
differences between cells will be adjusted before S-phase is initiated. Unlike normal cells, the 
transformed cells lack the ability to withdraw the G0 under suboptimal conditions. 
 
This article aims to summarize how normal and transformed cells relate to the G0-blocking 
and how individual factors determine the both cells relation to cell proliferation inhibition and 
"sustained proliferation." 
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INTRODUCTION 
Normal cells differ from tumour cells, in one fundamental capacity.  Whereas normal cells are 
subject to a proliferation control, tumour cells can escape from this control mechanism and 
display an inherent capacity to unlimited proliferation.  There is a fundamentally locical 
explanation for the existence of a control mechanism in normal cells. Such cells proliferate 
when they receive a signal to do so. This is the case during embryogenesis as well as in adult 
life. Basically cells proliferate to fulfil a need. When the task is completed, the cells will cease 
growing until they are stimulated to resume proliferation.   
Tumour cells have somehow acquired a capacity to escape from this important control 
mechanism. And this ability to overcome growth inhibitory signals is what makes tumour 
cells deleterious to the organism. Even though these fundamental differences were pinpointed 
some time ago (Dulbecco & Elkington  1971, Stoker 1973, Holley et. al. 1975) the key issue 
remains;  How can the finely tuned control mechanisms that operate in a narrow interval in 
the cell cycle be overcome during transformation. And more importantly; can these control 
mechanisms be reinstated in tumour cells in order to reverse the transformation process. 
Cancer issues in general have stimulated an enormous interest in the scientific community. It 
is believed that two million scientific articles with some bearing on cancer are published 
every year.  It is an impossible task to even attempt to systemise this information. So this 
paper attempts instead to focus on one key-issue, namely exit from and re-entry into the cell 
cycle, and moreover, how tumour cells act to avoid this gate control.  Emphasis will be on the 
activation of key oncogenes that occur in tumour cells during the transformation process. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 4 
 
MATERIAL AND METHODS 
Most articles were found in the databases; Google Scholar, PubMed and Web of knowledge. I 
used search-terms like ”sustained proliferation”, ”eukaryote cell cycle”, growth factor 
overexpression” and ”Cyclin overexpression”. The articles along with some papers kindly 
provided from my supervisor have formed the basis for my literature review. 
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LITERATURE REVIEW 
 
The normal cell cycle 
The current description of the cell cycle was formulated by JM Mitchison 1971: “The cell 
cycle of a growing cell is the period between the formation of the cell by the division of its 
mother and the time when the cell itself divides to form two daughters.” (Mitchison, 1971) 
 
The intermitotic cell cycle consists of four different phases, the G1 (presynthetic phase), S 
(synthesis of DNA), G2 (premitotic phase) and M (mitotic phase). This was proposed by 
Howard and Pelc after studying onion roots cells over time. (Howard and Pelc, 1953) Normal 
cells are also capable of leaving the cell cycle and enter a state of quiescence (G0). From 
which they can be restimulated to enter the cell cycle. 
 
Moreover in 1971 Mitchison suggested the existence of two parallel processes that build up 
the cell cycle. He performed his studies on growing cells from fission yeast 
Schizosaccharomyces pombe culture. One cycle includes DNA synthesis and mitosis 
(chromosome cycle), whereas the other includes cell enlargement, in which the cell doubles 
its components, (the growth or cytoplasmic cycle). (Mitchison,1971)  
The relationship between the two cycles had prevent been highlighted by Prescott who by 
studying  Amoeba proteus, concluded that a cell couldn’t divide until it has reached a critical 
size, and not until then initiate S-phase. (Prescott,1955) 
 
In the normal cell cycle different cyclins, cyclin-dependent kinases (CDKs) and their 
inhibitors regulate the cellular progress through the different phases in the cycle. In tumour 
cells the regulation is often deranged, and they can easier be triggered to proceed towards 
division. Another feature is that tumour cells can continue to cycle even with fundamental 
aberrations.  
For the cell to continue towards the cell cycle, CDKs are required to phosphorylate critical 
target proteins. CDKs are continuously expressed, in contrast to cyclins that are synthetized at 
different phases of the cell cycle, subject to need. The CDKs are activated by phosphorylation 
upon binding to cyclins. The cyclin protein-family consists of, at least 15 discovered proteins, 
four of them, cyclin D, E, A, and B are active in different parts of the cell cycle.  
(Hunter & Pines, 1994) 
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The first cyclin to accumulate in the cell cycle, in mid G1, is cyclin D and plays an important 
role by binding and activating CDK4. Cyclin D and CDK4 form a complex, which 
phosphorylates the retinoblastoma susceptibility protein (Rb).  
When cyclin D phosphorylates Rb, it releases the transcription factor, E2F, which in 
hypophosphorylated form is inactive. When the cell enters mitosis cellular phosphatases 
remove phosphate group from Rb and thus reconstructs hypophosphorylated form of Rb. 
(Hunter & Pines, 1994) 
The concentrations of cyclin D and E will also rise when quiescent cells are stimulated to re-
enter the cell cycle by appropriate stimulus. This results in the activation of cyclin D-CDK4 
and cyclin E-CDK2 at G1/S transition point. It causes phosphorylation of Rb and it will 
dissociate itself from the complex with E2F, and hence activate the target genes, such as DNA 
polymerase, cyclin E and thymidine kinase, and in this way stimulate the G1-progression. To 
provide stability trough the G1-S progression cyclin E-CDK2 also phosphorylates p27 and 
p21, that belong to the Cip/Kip protein family, these proteins inhibits cyclin E and hence 
function as tumour suppressors. Cyclin E also induces the up regulation of histone gene 
transcription by phosphorylation of p220npat, which also contributes to the shift from G1 to S. 
Cyclins are unstable proteins that are degraded in at least two different ways. One way 
involves the BCR ubiquitin ligase. The other is mediated through the Cul-3-medited ubiquitin 
proteasome pathway.(Tat Siu et. al., 2012)  
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The “If” and “when” decisions 
25 years ago Engström and Larsson proposed that when a cell progresses through the G1 it 
has to make two independent decisions. The first decision is made in early G1 (G1post 
mitosis) whether or not to continue its progression towards DNA-replication and mitosis. This 
is a strict yes/no decision, and it depends on the presence of certain growth factors. If there is 
a lack of growth factors, the cell will leave the cell cycle and enter the state of quiescence, G0.  
 
The next decision is a “when” decision, and is made in late G1, after the restriction point, 
(G1pre-synthesis). In contrast to the “if-decision” this is only a question of when to initiate 
the DNA-synthesis and the decision itself is made irrespective whether or not the cell has 
been exposed to suboptimal conditions. This decision accounts for most of the variability of 
the cell cycle. Larsson et al, provided evidence that cells that are younger than 3-4 hour, and 
thus located in the postmitotic phase of G1, prolonged their cell cycle with 8 hours after a 
serum-deprivation of only one hour.  It was also shown that cells older than four hours, and 
thereby located in presynthetic phase of G1, S or G2 did undergo mitosis irrespective whether 
or not serum was present. (Larsson, 1984) Whereas S, G2 and M-phases have a constant 
duration, G1 varied in length, and could be influenced by the presence of certain growth 
factors. (Dafgård, 1990) 
 
To be able to prove this Engström and Larsson used time lapse cinematography. A bottle 
containing exponentially growing cells was placed in an inverted microscope. A video camera 
system was attached for time elapse cinematography. In the starvation experiment the serum-
containing medium was removed, the cells washed in saline and serum free medium added. 
After the experiment lapsed serum was added. By subsequent development and analysis of 
the cells the intermitotic time position of each cell could be determined and hence the cellular 
age at the onset of the serum-starvation be estimated. (Larsson, 1984) 
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Sustained proliferative signalling 
A cell that sustains proliferative signalling can continue to divide even in a suboptimal 
environment, when it otherwise should be forced into cell arrest. Thus the tumour cell is 
equipped with a mechanism to avoid being captured in G0. The important question is how 
such cells succeed to avoid the “if”-decision in G1pm. 
 
In normal cells, the production of the proliferative signals are strictly controlled, thus they 
switch on relevant genes when a growth factor is added. To circumvent this, tumour cells, can 
produce their own growth factors and overexpress the receptors. Another way to sustain 
proliferation is to send signals to the normal cells in the  stroma and they will answer by 
producing growth factors that will operate in a paracrine fashion. They can also increase the 
amount of receptors expressed on the cell surface or activate protein in the downstream 
signalling pathway. (Hanahan & Weinberg, 2011). 
 
Over the last two decades a large number of proto-oncogenes have been discovered. The 
proto-oncogenes play an important role in the generation of cell growth and proliferation. For 
instance, proteins encoded by proto-oncogenes are often growth factor ligands and receptors, 
transcription factors, signal transducers and cell cycle regulators. These oncogenes often 
have similar functions, and contribute to tumour cell self-sufficiency for growth, division and 
survival. (Adamson, 1987) 
 
Growth factors as oncogene products 
It has generally been assumed that Growth Factors (GF) contribute to tumour formation, by 
binding to cell membrane receptors and thus stimulate cell proliferation. 
It has been shown that transformed cells grown in vitro require less serum. Moreover, in 
many types of cancer, a loss of requirement for specific GF’s in vivo has been established.  
In 1960, Cohen and Levi-Montalcini became the first persons to describe the Epidermal 
Growth Factor (EGF). EGF is structurally related to TGF- α (Transforming Growth Factor), 
and both binds to the same receptor. Some oncogene products have been found to be 
homologous to the Fibroblast Growth Factors (FGF). The first oncogene to be studied in this 
sense was hst (human stomach tumour) which is now official known as FGF-3.  
 
In several tumours the proto-oncogene sis is overexpressed which codes for the beta-chain, of 
an important growth factor, Platelet Derived Growth Factor (PDGF). PDGF is a potent 
mitogen, and binds to two cell-surface receptors, PDGFr α and β. Activation of PDGF 
receptors causes migration and proliferation of several cells, for instance fibroblasts, smooth 
muscle cells and monocytes. It’s assumed that a PDGF or PDGF-like molecule is produced in 
most transformed mesenchyme cells.  
Fibroblast Growth Factor and Epidermal Growth Factor both increase the early transcription 
of proto-oncogene fos, whereas PDGF induce c-myc.  (Goustin et. al., 1986)  
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Cell surface receptors as oncogene products 
Receptors with tyrosine kinase activity consist of three different parts, one extracellular 
domain, one trans-membrane hydrophobic part and one intracellular tail that have a tyrosine 
kinase activity. When a growth factor binds, it causes dimerization of the receptor, tyrosine 
phosphorylation and activation of the receptor tyrosine kinase. The tyrosine kinase then 
activates a lot of different effector molecules, several of them involved in the cell cycle. 
(Adamson, 1987) 
 
When an oncogene encodes growth factor receptors, it results in a constitutive dimerization 
and activation without binding a growth factor, which in turn leads to self-sufficiency. Several 
oncogenes that encode growth factor receptors have been found, for instance; erbB2, which is 
homologous to the EGF-receptor gene. Moreover, erbB encode a truncated growth factor 
receptor, which seems to be activated without presence of growth factors.  (Goustin, et. al., 
1986) 
 
The Ras oncogene 
Alterations in proteins belonging to Ras gene-family are the most commonly occurring in 
human tumours. The mutated version of Ras occurs in about 30% of all human tumours and 
95% of human pancreatic cancer. (Barbacid, 1990). Ras plays an important role as signal 
transducer of mitogenic signals, and as an on/off switch for variety of critical cellular 
activities, such as proliferation and differentiation.  
The three Ras-genes (K-Ras, N-Ras and H-Ras) are tightly regulated in normal cells, and a 
mutation in the Ras-genes can create constitutively active proteins, which in turn, can result in 
uncontrolled proliferation. (Takashima & Faller, 2013).  
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Active Ras is able to induce degradation of p27, a cyclin-Cdk-complex inhibitor. If Ras then 
is mutated and constitutively activated, it is possible that it causes an overexpression of cyclin 
E by down-regulating its inhibitor (Philipp-Staheli, et. al., 2000). When Ras oncogene results 
in a p21 product, may activate the growth factor pathway, without binding from a growth 
factor, or presence of its receptor (Goustin, et. al., 1986). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The Src oncogene 
In 1996 Brown and Cooper identified C-src as a cellular form of V-src, which was first traced 
in avian tumour virus (Rous sarcoma virus). Src is a non-receptor tyrosine kinase and function 
as a cellular transduction pathway in numerous cellular processes, including; differentiation, 
proliferation, survival, motility, cell to cell-adhesion and angiogenesis.  To be able to regulate 
these cell processes Src has to interact with several factors, such as; cell surface receptors 
(PDGF, EGF and FGF-receptors), steroid receptor hormones and many others. (Ishizawar & 
Parsons, 2004) 
 
An increased level of Src mRNA has been shown in many types of cancer, including 
pancreatic, hepatocellular and gastric cancer. Although it has been known for long that C-src 
plays an important role the in development and progression of cancer, we still don’t know its 
ultimate function. 
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When cellular signals that promote proliferation, motility or survival are mediated 
intracellular Src-family kinases are activated. These functions along with effects on cell-cell 
adhesions promotes the metastatic potential of the cells. (Yeatman, 2004) Src activation is 
very carefully controlled via phosphorylation. Inhibition of Src’s catalytic activity is achieved 
by phosphorylation upon Tyr-527 residue, thus it promotes an intermolecular interaction with 
the SH2 domain. In contrast, activation of Src is achieved by phosphorylating the Tyr-416 
residue. 
The v-Src which lacks this sequence, and are no longer capable of being regulated. The result 
is a constitutively active signal transduction pathway. (Xu et. al., 2012) 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
Jun, Fos and AP1 transcription factor 
Jun and Fos together form a transcription factor called Activating Protein-1 (AP-1). It consists 
of a mixture of hetero- and homo-dimer, between proteins in jun-family (c-jun, JunB and 
JunD) and fos-family (C-fos, FosB, Fra1 and Fra-2). The AP-1 formation transduces the 
growth factors messages to the nucleus, which leads to secondary gene expression.  AP-1 is 
involved in proliferation, differentiation and cell death. (Mechta-Grigoriou et al., 2001).  
 
Development of tumours is a multistep process, and AP-1 is probably involved in the control 
of cell proliferation via the signals to the nucleus. But, it should be noted that AP-1 also can 
have an anti-proliferative activity. It is not until c-JUN is activated by JUN amino-terminal 
kinases (JNK) that AP-1 completely promotes the cell-cycle progression. Consequently, the 
AP-1 complex induces transcription of the regulators that promotes the progression of the cell 
cycle factors, such as cyclin D, or represses the cell cycle inhibitor. 
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In contrast overexpression of JunB appears to be a antagonizing factor to the induction of 
cyclin D, and in this way has an inherent anti-proliferative activity. (Shaulian, E & Karin, M. 
2002)  
 
PTEN 
P13-Kinase and PTEN are two of the most frequent mutated proteins in cancer. PTEN 
encodes a phosphatase. PTENs particularly target is phosphatidylinositol-3,4,5-trisphosphate 
(PIP3) and phosphatidylinositol-3,4-biphosphate, which are specialized plasma membrane 
lipids. When the PI3K cellular signalling chain is active it produces these lipids. PTEN can 
then act like an off-switch for PI3K, by removing phosphate from the D3-position.  
It may be hypothesised that PTEN functions as a tumour suppressor. Receptor Tyrosine 
Kinase (RTK) on the cell surface membrane senses survival and cell growth signals and 
consequently activates PI3K via an enzyme, that generates PIP3 as well.  If PTEN is mutated 
it might result in an unregulated activation of PI3K.  The PI3K-pathway controls cell growth, 
survival and proliferation of the cell. When PIP3 is active it will require several kinases, 
including Phosphoinositide-Dependent Kinase 1 (PDK1) and the Protein Kinase b/Akt family. 
Eventually Akt-targets will get phosphorylated partially by phosphorylation by PDK1, and 
these will play an important role in regulating; apoptosis, proliferation, nutrient response 
glucose homeostasis, cell size and DNA-damage.  
In conclusion, inactivation of PTEN can lead to a constitutive activation of the Akt signalling 
pathway. (Sansal & Sellers, 2004). 
 
 
 
 
 
 
 
 
The Myc oncogene  
Like other proto-oncogenes the expression of C-myc in normal tissue is carefully regulated by 
external and internal signals. C-myc is known to regulate proliferation, apoptosis, 
differentiation and metabolism.  
It has been shown that resting cells only express a small amount of C-myc, while growing 
cells, stimulated by growth factors transiently express an increased amount of C-myc. The 
activation of C-myc in cancer can have different causes, for example; chromosomal 
translocation or gene amplification – which increases the expression of Myc.  
The role of C-myc in the cell cycle progression is not clearly known, but one model suggests 
that C-myc accelerates the progression trough G1 and S and hence promoting cell 
proliferation.  
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Moreover, it has been shown that C-myc induces cyclin D, cyclin E, CDK4 and inhibits p27; 
which is a CDK-inhibitor. Also, C-myc is involved in the cell cycle by its direct target 
cdc25A which product activates both CDK2 and CDK4.  Deregulated C-myc also induces 
cyclin E directly. In a recent study it has been shown that C-myc together with Ras also to 
induces the CDK1 promoter and that C-myc therefor plays a many sided role in tumorgenesis.  
(Dang, 1999) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Overexpression of cyclin E 
Cyclin E plays an important role in the progress though the G1 phase of the cell cycle. Along 
with cyclin D-Cdk2 it phosphorylates the retinoblastoma (Rb), and makes the G1/S-transition 
possible.  
Lately different types of cancer cells have been shown to express high levels of cyclin E and 
it have been shown that an overexpression of cyclin E correlates with increased tumour 
aggression.    
One way to derange the normal control of cyclin E expression is via loss-of-function mutation 
sustained by the gene FBWX7. This gene encodes tumour suppressor protein fbw7, whose 
assignment is to provide substrate specificity for an ubiquitin ligase complex, which target 
several oncoproteins for degradation. This is only one of many ways by which cyclin E can be 
deregulated in cancer cells. To be able to understand the oncogenic effect of cyclin E, we 
have to understand the complexity of its function and regulation.  
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Cyclin E can stimulate its own transcription via a positive feedback and transcription of the 
cyclin E genes is activated during G1. This transcription depends on mitogenic input, which 
includes E2F and Myc activities. If an overexpression of cyclin E occurs, the step that 
normally would be rate-limiting becomes partially independent of the mitogens. 
 
Cip/Kip proteins, and in particular p21 and p27, inhibit cyclin-Cdk complexes. By activating 
p53, cyclin can induce p21 expression. It’s shown that p21 and p27 is both inhibitors and 
substrates for cyclin E-Cdk2. Active cyclin E-Cdk2 can phosphorylate p27 and p21 if its 
Cdk2-bound, resulting in triggering their degradation.     
 
Except from phosphorylating Rb cyclin E phosphorylate CBP/p300 and this stimulates 
transcription activity and cell cycle progression. (Tat Siu, et. al., 2012) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 15 
 
DISCUSSION 
In this article, one of the most fundamental differences between a normal cell and a tumour 
cell has been reviewed and discussed. Normal cells are under a strict proliferation control. 
The basis for this mechanism is that a cell should be able to proliferate as long as there is a 
need for an increased cell number. When this need is fulfilled, normal cells sense the lack of 
growth stimulatory signals and exit from the cell cycle and enter a reversible state of 
quiescence termed G0. During transformation, cells lose this ability to cease multiplying in 
response to decreased growth signals and hence continue to proliferate also under suboptimal 
conditions. This characteristic of the transformed phenotype is the most crucial and 
fundamental change that the normal cell has to undergo during tumourgenesis. It has therefore 
been the aim of this article to highlight molecular events directly coupled to this change. 
 
It has been proposed that cells have to make two independent decisions in order to progress 
towards mitosis. The first decision – “If” which is made during early G1, and is clearly 
influenced by external factors as polypeptide growth factors, cell contacts and surface 
anchorage. This dependence on external signals is pivotal to the normal phenotype. Thus, it is 
the inability to make an active “if”-decision that is the key to understanding transformation. 
(Larsson, 1984) 
 
According to the existing literature it almost a dogma that it is the combination of activated 
oncogenes that contribute to tumour development. There are two principally different ways by 
which oncogenes can contribute to the transformation process. Either the proto-oncogene – or 
the cellular oncogene – can be stimulated to enhanced transcription. The consequence would 
then be an increased amount of perfectly normal oncogene product that will be available for 
the transformation process. Examples of this activation can be seen during gene amplification 
or translocation – N-myc amplification in neuroblastoma is a classic example of the former 
and C-myc translocation in Burkitts lymphoma is an example of the latter. In each of these 
cases, increased amounts of N-myc or C-myc protein drives the proliferative circuit and 
causes cells to acquire a transformed phenotype.  
The second alternative is that changes in the coding exons of relevant oncogenes but with an 
unchanged promoter-enhancer apparatus will yield a normal amount of altered protein 
product. Classical examples are point mutations as in the Ras-gene or fusion genes as e.g. the 
abl-bcr fusion gene. 
 
With respect to function, oncogene products can affect different levels in the chain of events 
leading to cell proliferation. Oncogene products can act as growth factors, membrane 
receptors (complete or truncated), G-proteins, intracellular tyrosine kinases, nuclear 
transcription factors etc. It is clear that we have only been scratching the surface of this 
intricate signalling system. 
 
But it is important that focus remains on the key issue. How is the cells normal control 
mechanism operating in G1 effectively overrun by transforming factors? Only when this 
critical issue is understood, can cancer research take a well-earned leap forward. 
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